Sight Sciences Inc Stock News

Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Macauley Kilbane - William Blair Phil Dantoin - Piper Sandler Nelson Cox - Lake...

MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on ...

The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease

MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference, in New York, NY.

Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants Thomas Stephan - Stifel Joseph Conway - Needham & Company Felipe Lamar - Cit...

MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thur...

The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives

Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for th...